Huang Kaiyue, Lv Mi, Zheng Ting, Wang Fengyun, Tang Xudong, Lv Lin
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Graduate school, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2024 Nov 28;15:1475366. doi: 10.3389/fphar.2024.1475366. eCollection 2024.
To systematically evaluate the herbal placebo response in randomized controlled trials (RCTs) of herbal medicine on irritable bowel syndrome (IBS).
We searched for RCTs with herbal placebo groups for IBS in PubMed, EMBASE, the Cochrane Library, the China National Knowledge Infrastructure (CNKI), the Wan Fang database and Sinomed database from 31 January 1994 to November 2023, and the quality of the literature was evaluated by the Cochrane risk of bias assessment criteria. The primary outcome indicators were response rate, abdominal pain and stool improvement rate, which were analyzed by single-group rate meta-analysis. Secondary outcomes were analyzed in subgroups based on diagnostic criteria, duration of treatment, subtype, research locations, placebo form, and presence of herbal ingredients to look for factors affecting respond rate.
The study included 24 papers, involving a total of 2,596 patients. Of these, 1151 IBS patients were treated with the herbal placebo. The placebo response rate in IBS patients in the herbal placebo group was 37% (P < 0.01,I = 75%). A total of 287 patients in five studies were given the herbal placebo, and the improvement rate of abdominal pain was 29% (P = 0.83, I = 0%). Four studies enrolled a total of 212 patients with IBS who received herbal placebo, and the stool improvement rate was 46% (P = 0.02 < 0.05, I = 71%). The research locations and treatment duration were sources of heterogeneity (P < 0.05).
There is a significant herbal placebo response in patients with IBS. Different research locations and treatment durations are major sources of heterogeneity that may affect IBS patient response rates. The addition of a low dose of herbal ingredients when simulating an herbal placebo does not exaggerate the therapeutic effect of the placebo. There is a lack of uniformity and standardization in the preparation and evaluation of herbal placebos.
系统评价草药安慰剂在肠易激综合征(IBS)草药医学随机对照试验(RCT)中的反应。
我们在1994年1月31日至2023年11月期间,检索了PubMed、EMBASE、Cochrane图书馆、中国知网(CNKI)、万方数据库和中国生物医学文献数据库(Sinomed)中设置草药安慰剂组的IBS随机对照试验,采用Cochrane偏倚风险评估标准对文献质量进行评价。主要结局指标为有效率、腹痛改善率和大便改善率,采用单组率Meta分析进行分析。次要结局根据诊断标准、治疗持续时间、亚型、研究地点、安慰剂形式和草药成分的存在情况进行亚组分析,以寻找影响有效率的因素。
该研究纳入24篇论文,共涉及2596例患者。其中,1151例IBS患者接受了草药安慰剂治疗。草药安慰剂组IBS患者的安慰剂有效率为37%(P<0.01,I=75%)。五项研究中共有287例患者接受了草药安慰剂治疗,腹痛改善率为29%(P=0.83,I=0%)。四项研究共纳入212例接受草药安慰剂治疗的IBS患者,大便改善率为46%(P=0.02<0.05,I=71%)。研究地点和治疗持续时间是异质性的来源(P<0.05)。
IBS患者存在显著的草药安慰剂反应。不同的研究地点和治疗持续时间是可能影响IBS患者有效率的主要异质性来源。模拟草药安慰剂时添加低剂量草药成分不会夸大安慰剂的治疗效果。草药安慰剂的制备和评价缺乏一致性和标准化。